Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous ...

Shares of IBD 50 stock Axsome Therapeutics tumbled Tuesday after the biotech reported mixed results for its drug, Sunosi, in adults with attention deficit hyperactivity disorder. The company ...

Axsome Therapeutics reported strong Q1 2025 earnings, with revenue and EPS beats driven by Auvelity and Sunosi. See why I maintain my sell rating on AXSM stock.

Axsome Therapeutics, Inc. has announced a new $570 million term loan and revolving credit facility with Blackstone Life Sciences and Blackstone Credit & Insurance, which replaces its previous term ...

HC Wainwright reissued their buy rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a research report report published on Thursday morning,Benzinga reports. They currently ...

Herriot Tabuteau, MD, Chief Executive Officer of Axsome Therapeutics, said, “Today’s approval of SYMBRAVO marks an important milestone for the migraine community by providing a rationally ...

Total 4Q and full year 2024 net product revenue of $118.8 million and $385.7 million, respectively, representing 66% and 88% year-over-year growth Auvelity ® 4Q and full year 2024 net product ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced financial results for the first ...

State of New Jersey Common Pension Fund D decreased its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 1.9% during the 4th quarter, HoldingsChannel reports.

In January, Axsome Therapeutics reported preliminary Auvelity net product sales are expected to be approximately $92.6 million and $291.4 million for the fourth quarter and full year of 2024 ...